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Polymorphisms in CYP2D6 and CYP2C19 affect the efficacy 
and safety of tricyclics, with some drugs being affected by 
CYP2D6 only, and others by both polymorphic enzymes. 
Amitriptyline, clomipramine, doxepin, imipramine, 
and trimipramine are demethylated by CYP2C19 to 
pharmacologically active metabolites. These drugs and their 
metabolites, along with desipramine and nortriptyline, 
undergo hydroxylation by CYP2D6 to less active metabolites. 
Evidence from published literature is presented for CYP2D6 
and CYP2C19 genotype–directed dosing of tricyclic 
antidepressants.
The use of tricyclics to treat psychological disorders has declined 
in part because of the occurrence of undesirable side effects. 
Although tricyclics are still used to treat depression,1 their main 
therapeutic use is often for pain management.2,3 Interindividual 
differences in side effects and treatment response have been 
associated with variability of tricyclic plasma concentrations.4,5 
Because both enzymes influence plasma concentrations, the 
effectiveness and tolerability of tricyclics are affected by CYP2D6 
metabolism and partially by CYP2C19 metabolism.4 The purpose 
of this guideline is to provide information regarding how to use 
existing CYP2D6 and/or CYP2C19 genotyping test results to guide 
dosing of tricyclics for psychological disorders and pain manage-
ment, focusing particularly on amitriptyline and nortriptyline.
Optimal therapeutic plasma concentrations for the tricyclics 
have been defined.6 Poor or ultrarapid metabolizers of CYP2D6 
and CYP2C19 may have tricyclic plasma concentrations outside 
the recommended therapeutic range, thereby increasing the risk 
of treatment failure or side effects.7–10 Therefore, this guideline 
takes into consideration both clinical outcomes and observed 
tricyclic plasma concentrations based on genotype/phenotype 
characteristics. Detailed guidelines for use of other laboratory 
tests including therapeutic drug monitoring of tricyclics are 
beyond the scope of this article. The Clinical Pharmacogenetics 
Implementation Consortium (CPIC) of the National Institutes 
of Health’s Pharmacogenomics Research Network develops 
peer-reviewed gene–drug guidelines that are published and 
updated periodically at http://www.pharmgkb.org based on new 
developments in the field.
FOCUSED LITERATURE REVIEW
A systematic literature review focused on CYP2D6 and 
CYP2C19 genotyping and its relevance to gene-based dosing of 
tricyclics was conducted (see Supplementary Data online). This 
guideline was developed based on interpretation of the literature 
by the authors and experts in the field.
GENES: CYP2D6 AND CYP2C19
CYP2D6 background
The CYP2D6 gene is highly polymorphic.11 More than 100 known 
allelic variants and subvariants have been identified, and there 
are substantial ethnic differences in observed allele frequencies 
(Supplementary Data online). The most commonly reported 
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alleles are categorized into functional groups as follows: functional 
(e.g., CYP2D6*1 and *2), reduced function (e.g., CYP2D6*9, *10, 
and *41), and nonfunctional (e.g., CYP2D6*3–*6).11,12 Because 
CYP2D6 is subject to deletions or duplications, most clinical labo-
ratories also report copy number. Deletions are indicated by the 
CYP2D6*5 allele, and gene duplications are denoted by an “xN” 
following the allele (e.g., CYP2D6*1xN, where xN represents the 
number of CYPD6 gene copies).
CYP2C19 background
Similar to CYP2D6, the CYP2C19 gene is highly polymorphic; 
more than 30 known allelic variants and subvariants have been 
identified.13 Although there are ethnic differences in allele fre-
quencies (Supplementary Data online), the majority of patients 
carry a CYP2C19*1, *2, or *17 allele.13 CYP2C19*1 is the wild-type 
allele encoding a fully functional enzyme, and CYP2C19*2 is the 
most common loss-of-function allele. Multiple CYP2C19 loss-of-
function alleles have been identified (e.g., CYP2C19*3–*8), but 
their allele frequencies are <1%, with the exception of CYP2C19*3, 
which has a frequency of 2–15% in Asians.13
The CYP2C19*17 allele results in enhanced gene transcription 
purportedly leading to increased metabolic activity.14 However, 
the clinical importance of the CYP2C19*17 allele is a matter 
of debate. Some studies indicate that CYP2C19*17 enhances 
clopidogrel response and increases the probability of therapeu-
tic failure for proton pump inhibitors or antidepressants due to 
altered drug plasma concentrations, but there are conflicting 
clinical data.13–19
Genetic test interpretation
Clinical laboratories usually test for the more frequently observed 
CYP2D6 and CYP2C19 genetic variants and translate the results 
into star-allele (*) nomenclature. Each star-allele, or haplotype, is 
defined by a specific combination of single-nucleotide polymor-
phisms and/or other genetic variants within the gene locus of 
either CYP2D6 or CYP2C19.11,13 Genetic test results are reported 
as the summary of inherited maternal and paternal star-alleles 
referred to as a diplotype (e.g., CYP2D6*1/*2 and CYP2C19*1/*1). 
See Supplementary Data online for the more frequently observed 
alleles and their functional status.
Scoring systems have been developed in an attempt to provide 
a uniform approach to quantitate the predicted functional status 
of CYP2D6 alleles as follows: 1 for functional, 0.5 for reduced 
function, and 0 for nonfunctional alleles (Supplementary Data 
online).11,12 The activity value for each allele of the diplotype 
is totaled to provide a CYP2D6 activity score. If CYP2D6 gene 
duplications are detected, the activity value of the duplicated 
allele is multiplied by the number of duplications present before 
calculating the activity score. The CYP2D6 activity score is used 
to assign phenotype in this guideline as follows: patients with 
an activity score of 0 are classified as poor metabolizers, those 
with a score of 0.5 are intermediate metabolizers, those with a 
score from 1.0 to 2.0 are extensive metabolizers, and those with 
a score >2.0 are classified as ultrarapid metabolizers (Table 1, 
Supplementary Data online). Extensive metabolizers are con-
sidered to have normal CYP2D6 enzyme activity.
There is a lack of consensus with regard to whether patients 
with a CYP2D6 activity score of 1.0 should be assigned an exten-
sive or intermediate phenotype.11 Pharmacokinetic data suggest 
that patients with an activity score of 1.0 have a higher CYP2D6 
metabolic capacity as compared with patients with an activity 
score of 0.5 but less CYP2D6 enzyme activity as compared 
with patients with an activity score of 2.0.12 Patients with one 
functional and one nonfunctional CYP2D6 allele do not have 
Table 1 Assignment of likely phenotypes based on diplotypes
Likely phenotype Activity scorea Genotypes Examples of diplotypes
Assignment of CyP2D6 phenotype
 Ultrarapid metabolizer (~1–2% of patients)b >2.0 An individual carrying duplications of functional 
alleles
(*1/*1)xN, (*1/*2)xN, 
(*2/*2)xNc
 Extensive metabolizer (~77–92% of patients) 1.0–2.0d An individual carrying two functional alleles or 
two reduced function alleles or one functional and 
nonfunctional allele or one functional and reduced 
function allele
*1/*1, *1/*2, *2/*2, *1/*9, 
*1/*41, *41/*41, *1/*5, 
*1/*4
 Intermediate metabolizer (~2–11% of patients) 0.5 An individual carrying one reduced function and 
one nonfunctional allele
*4/*41, *5/*9, *4/*10
 Poor metabolizers (~5–10% of patients) 0 An individual carrying only nonfunctional alleles *4/*4, *3/*4, *5/*5, *5/*6
Assignment of CyP2C19 phenotype
 Ultrarapid metabolizer (~5–30% of patients)e An individual carrying two gain-of-function alleles 
or one functional allele and one gain-of-function 
allele
*17/*17, *1/*17
 Extensive metabolizer (~35–50% of patients) An individual carrying two functional alleles *1/*1
 Intermediate metabolizer (~18–45% of patients) An individual carrying one functional allele and one 
loss-of-function allele
*1/*2, *1/*3
 Poor metabolizers (~2–15% of patients) An individual carrying two loss-of-function alleles *2/*2, *2/*3, *3/*3
aSee Supplementary Data for additional information about CyP2D6 activity score and its limitations. bCyP2D6 metabolizer status frequencies are based on data from Caucasians 
and may differ from other ethnicities. cxN represents the number of CYP2D6 gene copies. dPatients with an activity score of 1.0 may be classified as intermediate metabolizers by 
some reference laboratories. eCyP2C19 metabolizer status frequencies are based on average multiethnic frequency.
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significantly different nortriptyline plasma concentrations as 
compared with patients with two functional CYP2D6 alleles,20 
although another study reported conflicting data.7 Herein, we 
classified patients with a CYP2D6 activity score of 1.0 as exten-
sive metabolizers, which is analogous to the CPIC guideline for 
codeine.11
The predicted CYP2C19 phenotype based on the diplotype 
(Table 1 and Supplementary Data online) is consistent with 
the CPIC guideline for clopidogrel.13 Patients with two func-
tional alleles are categorized as extensive metabolizers, which 
is considered normal CYP2C19 enzyme activity. Individuals 
carrying one or two loss-of-function alleles are considered 
intermediate and poor metabolizers, respectively. Patients 
with two gain-of-function alleles are classified as ultrarapid 
metabolizers. The predicted phenotype for a patient carrying 
the CYP2C19*17 gain-of-function allele in combination with a 
loss-of-function allele is a matter of debate. Limited data sug-
gest that CYP2C19*17 may not compensate for the CYP2C19*2 
allele.15,21
Reference laboratories use varying methods to assign pheno-
types. Before pharmacotherapy modifications are made based 
on this guideline, it is advisable to determine a patient’s pheno-
type as described above.
Available genetic test options
CYP2D6 and CYP2C19 genotyping is available from several ref-
erence laboratories (see Supplementary Data online and http://
www.pharmgkb.org).
Incidental findings
Independent of drug metabolism and response, there are cur-
rently no diseases or conditions that have been convincingly 
linked to variants in the CYP2D6 or CYP2C19 genes.11,13 
Reports describing an association between CYP2D6 ultrarapid 
metabolizers and suicidality, and CYP2C19 polymorphisms and 
depressive symptoms are available.22–24 These associations are 
poorly understood and may be explained by alterations in either 
drug or endogenous substrate metabolism.
DRUGS: AMITRIPTYLINE AND NORTRIPTYLINE
Background
Tricyclics are mixed serotonin and norepinephrine reuptake 
inhibitors used to treat several disease states including depres-
sion, obsessive–compulsive disorder, and neuropathic pain 
in addition to migraine prophylaxis. The tricyclics have simi-
lar but distinct chemical structures referred to as tertiary and 
secondary amines. The pharmacological properties of the ter-
tiary and secondary amines differ, with tertiary amines having 
a more pronounced serotonergic effect and secondary amines 
having a greater noradrenergic effect (Supplementary Data 
online).25,26 The tertiary amines (e.g., amitriptyline) are mainly 
metabolized by CYP2C19 to desmethyl metabolites (Figure 1), 
also referred to as secondary amines (e.g., nortriptyline). It 
should be noted that the desmethyl metabolites, nortriptyline 
as well as desipramine, are antidepressant drugs themselves 
with distinct clinical features that differ from the parent drugs 
amitriptyline and imipramine. Both the tertiary and second-
ary amines are metabolized by CYP2D6 to less active hydroxy 
metabolites (Figure 1, Supplementary Data online). CYP2C19 
impacts the ratio of tertiary to secondary amine plasma concen-
trations but may have less influence on overall drug clearance 
than CYP2D6.27 However, CYP2C19 metabolism may modu-
late antidepressant activity and side effects through the phar-
macological actions of the tertiary amines. Serotonin reuptake 
inhibition is expected be more pronounced in CYP2C19 poor 
metabolizers due to the decreased conversion of tertiary to sec-
ondary amines.26
Patients may be predisposed to treatment failure or adverse 
effects due to polymorphisms in CYP2D6 and CYP2C19 alter-
ing drug clearance or the ratio of parent drug to metabolites, 
respectively. Tricyclics are associated with multiple adverse 
effects, which can cause patients to fail therapy. Common 
adverse effects include anticholinergic, central nervous system, 
and cardiac effects. Tertiary and secondary amines along with 
their metabolites have unique side-effect profiles as detailed in 
Supplementary Data online.
Both amitriptyline and nortriptyline are used as model drugs 
for this guideline because the majority of pharmacogenomic 
studies have focused on these two drugs. However, the results of 
these studies may apply to other tricyclics because these drugs 
have comparable pharmacokinetic properties.4,8 Tricyclics are 
well absorbed from the gastrointestinal tract, and the average 
extent of first-pass metabolism is ~50%, although the average 
first-pass metabolism of doxepin may be closer to 70%.4 The 
clearance of tricyclics is mostly a linear process, but satura-
tion of the hydroxylation pathway may occur at higher plasma 
concentrations for certain tricyclics, including imipramine and 
desipramine.4,28 In addition, extrapolated dose adjustments 
based on metabolizer status are similar across the tricyclic class.8 
Because some studies investigating the influence of CYP2D6 
and/or CYP2C19 genotype/phenotype on the pharmacokinetics 
of tricyclics used a single dose, it should be noted that tricyclic 
metabolism is thought to be similar after single and multiple 
dosing.5
Linking genetic variability to variability in drug-related 
 phenotypes
Psychiatric disorders such as depression have a 30–50% failure 
rate with initial treatment, which may, in part, be attributed to 
adverse effects or altered plasma concentrations.9,29 There is 
substantial evidence linking CYP2D6 and CYP2C19 genotypes 
to phenotypic variability in tricyclic side-effect and pharma-
cokinetic profiles. Modifying pharmacotherapy for patients 
Figure 1 Major metabolic pathway of amitriptyline and nortriptyline.
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who have CYP2D6 or CYP2C19 genomic variants that affect 
drug efficacy and safety could potentially improve clinical 
outcomes and reduce the failure rate of initial treatment. The 
application of a grading system to the evidence linking CYP2D6 
and CYP2C19 genotypic variations to phenotypic variability in 
response to amitriptyline or nortriptyline indicates a high qual-
ity of evidence in the majority of cases (Supplementary Data 
online). This body of evidence, rather than randomized clinical 
trials, provides the basis for amitriptyline and nortriptyline dos-
ing recommendations in Tables 2 and 3. Because the tricyclics 
have comparable pharmacokinetic properties, it may be reason-
able to apply this guideline to other tricyclics, including clomi-
pramine, desipramine, doxepin, imipramine, and trimipramine 
(Supplementary Data online), with the acknowledgment that 
there are fewer data supporting dose adjustments for these drugs 
than for amitriptyline or nortriptyline.
Table 2 Dosing recommendations for amitriptyline and nortriptyline based on CYP2D6 phenotype
phenotype implication Therapeutic recommendation
Classification of 
recommendationa
CyP2D6 ultrarapid 
metabolizer
Increased metabolism of tricyclics to less 
active compounds as compared with extensive 
metabolizers
Avoid tricyclic use due to potential lack of efficacy. 
Consider alternative drug not metabolized by 
CyP2D6
Strong
Lower plasma concentrations will increase 
probability of pharmacotherapy failure
If a tricyclic is warranted, consider increasing the 
starting dose.b Use therapeutic drug monitoring to 
guide dose adjustments
CyP2D6 extensive 
metabolizer
Normal metabolism of tricyclics Initiate therapy with recommended starting doseb Strong
CyP2D6 intermediate 
metabolizer
Reduced metabolism of tricyclics to less active 
compounds as compared with extensive metabolizers
Consider 25% reduction of recommended starting 
dose.b Use therapeutic drug monitoring to guide 
dose adjustments
Moderate
Higher plasma concentrations will increase the 
probability of side effects
CyP2D6 poor  
metabolizer
Greatly reduced metabolism of tricyclics to less active 
compounds as compared with extensive metabolizers
Avoid tricyclic use due to potential for side effects. 
Consider alternative drug not metabolized by 
CyP2D6
Strong
Higher plasma concentrations will increase the 
probability of side effects
If a tricyclic is warranted, consider a 50% reduction 
of recommended starting dose.b Use therapeutic 
drug monitoring to guide dose adjustments
If CYP2C19 genotyping results are also available, see Table 3 for CYP2C19-based dosing recommendations along with Supplementary Data online. Dosing recommendations 
apply only to higher initial doses of amitriptyline or nortriptyline for treatment of conditions such as depression. See “Other Considerations” for dosing recommendations for 
conditions in which lower initial doses are used, such as neuropathic pain. For the dosing guidelines for clomipramine, desipramine, doxepin, imipramine, and trimipramine, see 
Supplementary Data online.
aThe rating scheme for the recommendation classification is described in the Supplementary Data online. bPatients may receive an initial low dose of tricyclics, which is then 
increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.
Table 3 Dosing recommendations of amitriptyline based on CYP2C19 phenotype
phenotype implication Therapeutic recommendation
Classification of 
recommendationa
CyP2C19 ultrarapid 
metabolizer
Increased metabolism of amitriptyline as compared 
with extensive metabolizers
Consider alternative drug not metabolized by 
CyP2C19
Optional
If a tricyclic is warranted, use therapeutic drug 
monitoring to guide dose adjustments
CyP2C19 extensive 
metabolizer
Normal metabolism of amitriptyline Initiate therapy with recommended starting 
doseb
Strong
CyP2C19  
intermediate 
metabolizer
Reduced metabolism of amitriptyline as compared 
with extensive metabolizers
Initiate therapy with recommended starting 
doseb
Strong
CyP2C19 poor 
metabolizer
Greatly reduced metabolism of amitriptyline as 
compared with extensive metabolizers
Consider a 50% reduction of recommended 
starting dose.b Use therapeutic drug monitoring 
to guide dose adjustments
Moderate
Higher plasma concentrations of amitriptyline will 
increase the probability of side effects
If CYP2D6 genotyping results are also available, see Table 2 for CYP2D6-based dosing recommendations along with Supplementary Data online. Dosing recommendations 
apply only to higher initial doses of amitriptyline for treatment of conditions such as depression. See “Other Considerations” for dosing recommendations for conditions at 
which lower initial doses are used, such as neuropathic pain. For dosing guidelines for clomipramine, doxepin, imipramine, and trimipramine, see Supplementary Data online.
aThe rating scheme for the recommendation classification is described in the Supplementary Data online. bPatients may receive an initial low dose of tricyclics, which is then 
increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.
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Therapeutic recommendations
CYP2D6 dosing recommendations. For neuropathic pain treat-
ment, in which lower initial doses of tricyclics are used, 
gene-based dosing recommendations are found in the “Other 
Considerations” section. Table 2 summarizes the gene-based 
dosing recommendations for amitriptyline and nortriptyline 
based on CYP2D6 phenotype for situations requiring a higher 
initial dose, such as depression treatment. The recommended 
starting dose of amitriptyline or nortriptyline does not need 
adjustment based on genotype for CYP2D6 extensive metabo-
lizers. A 25% reduction of the recommended dose may be 
considered for CYP2D6 intermediate metabolizers.30 Because 
patients with a CYP2D6 activity score of 1.0 are inconsistently 
categorized as intermediate or extensive metabolizers in the 
literature, these are difficult to evaluate, resulting in a moder-
ate recommendation classification.
CYP2D6 ultrarapid metabolizers have a higher probability of 
failing amitriptyline or nortriptyline pharmacotherapy due to 
subtherapeutic plasma concentrations, and therefore alternative 
agents are preferred. There are documented cases of CYP2D6 
ultrarapid metabolizers receiving large doses of nortriptyline 
to achieve therapeutic concentrations.10 However, very high 
plasma concentrations of the nortriptyline hydroxy metabolite 
were present, which may increase the risk for cardiotoxicity. If a 
tricyclic is warranted, there are insufficient data in the literature 
to calculate a starting dose for a patient with CYP2D6 ultrarapid 
metabolizer status, and therapeutic drug monitoring is strongly 
recommended. Adverse effects are more likely in CYP2D6 poor 
metabolizers due to elevated tricyclic plasma concentrations,31 
therefore, alternative agents are preferred. If a tricyclic is war-
ranted, consider a 50% reduction of the usual dose; therapeutic 
drug monitoring is strongly recommended.
CYP2C19 dosing recommendations. Dosing recommendations for 
neuropathic pain treatment with amitriptyline are discussed in 
the “Other Considerations” section. Table 3 summarizes the 
gene-based dosing recommendations for CYP2C19 and ami-
triptyline when higher initial starting doses are warranted. The 
usual starting dose of amitriptyline may be used in CYP2C19 
extensive and intermediate metabolizers. Although CYP2C19 
intermediate metabolizers would be expected to have a modest 
increase in the ratio of amitriptyline to nortriptyline plasma 
concentrations, the evidence does not indicate that CYP2C19 
intermediate metabolizers should receive an alternative dose.
Patients taking amitriptyline who are CYP2C19 ultrarapid 
metabolizers may be at risk of having altered plasma concen-
trations or adverse events. Although the CYP2C19*17 allele did 
not alter the sum of amitriptyline plus nortriptyline plasma con-
centrations, it was associated with higher nortriptyline plasma 
concentrations, possibly increasing the risk of adverse events.15 
For patients taking amitriptyline, extrapolated pharmacokinetic 
data suggest that CYP2C19 ultrarapid metabolizers may need 
a dose increase.8 Due to the need for further studies investi-
gating the clinical importance of the CYP2C19*17 allele and 
the possibility of altered tricyclic concentrations, we recom-
mend consideration of an alternative tricyclic or other drug 
not affected by CYP2C19. Because the clinical importance of 
CYP2C19*17 is currently poorly understood, this recommenda-
tion is classified as optional. If amitriptyline is administered to a 
CYP2C19 ultrarapid metabolizer, therapeutic drug monitoring 
is recommended.
CYP2C19 poor metabolizers are expected to have a greater 
ratio of amitriptyline to nortriptyline plasma concentrations.32 
The elevated amitriptyline plasma concentrations may increase 
the chance of a patient experiencing side effects. Consider a 50% 
reduction of the usual amitriptyline starting dose along with 
therapeutic drug monitoring.8
CYP2D6 and CYP2C19 combined dosing recommendations. Although 
specific combinations of CYP2D6 and CYP2C19 alleles are 
likely to result in additive effects on the pharmacokinetic 
properties of tricyclics, little information is available on how to 
adjust initial doses based on combined genotype information. 
Patients carrying at least one CYP2D6 nonfunctional allele and 
two CYP2C19 functional alleles had an increased risk of expe-
riencing side effects when administered amitriptyline, whereas 
patients with at least one CYP2C19 loss-of-function allele and 
two CYP2D6 functional alleles had a low risk of experienc-
ing side effects.10,33 Because there is only sparse clinical evi-
dence for an additive effect of CYP2D6 and CYP2C19 on tri-
cyclic dosing, the recommendations are classified as optional 
(Supplementary Data online).
Other considerations
Gene-based dosing recommendations for neuropathic pain treatment. 
Amitriptyline is often used at lower dosages (e.g., 0.1 mg/kg/
day in pediatric patients) for treatment of neuropathic pain 
than when used for depressive disorders.2,3 Because of the 
lower dosage, it is less likely that CYP2D6 or CYP2C19 poor or 
intermediate metabolizers will experience adverse effects due 
to supratherapeutic plasma concentrations of amitriptyline.34 
Therefore, we recommend no dose modifications for poor 
or intermediate metabolizers when prescribed amitriptyline 
at a lower dose for treatment of neuropathic pain, but these 
patients should be monitored closely for side effects. If larger 
doses of amitriptyline are warranted, we recommend following 
the gene-based dosing guidelines presented in Tables 2 and 3.
Providing dose recommendations for CYP2C19 ultrarapid 
metabolizers when amitriptyline is prescribed at lower doses for 
neuropathic pain treatment is difficult. On the basis of predicted 
and observed pharmacokinetic data, CYP2D6 ultrarapid metab-
olizers are at risk of failing amitriptyline therapy for neuropathic 
pain, and thus alternative agents such as gabapentin should be 
considered.35 Although little information is available on how to 
adjust initial amitriptyline doses based on combined CYP2D6 
and CYP2C19 genetic results when treating neuropathic pain, 
caution should be used when patients have a combination of 
poor or ultrarapid phenotypes (e.g., a CYP2D6 poor metabolizer 
also having CYP2C19 ultrarapid or poor metabolism).
Consideration of drug interactions and patient characteristics. 
Patients treated for psychiatric disorders often require  multiple 
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 medications, which can influence tricyclic plasma concen-
trations, side effects, and therapeutic failure.4 For example, 
patients taking amitriptyline in combination with a potent 
CYP2D6 inhibitor, such as fluoxetine, may have dramatic 
increases in plasma concentrations.36 It has been suggested 
that patients taking strong CYP2D6 inhibitors should be 
treated similarly to CYP2D6 poor metabolizers.11 In addition, 
patients with increased age, liver disease, and reduced renal 
function may require reduced doses of tricyclics.4,37,38 Drug–
drug interactions along with patient characteristics should be 
considered in addition to the gene-based dosing recommenda-
tions presented herein.
Minor metabolic pathways of tricyclics. Other cytochrome P450 
enzymes, including CYP3A4 and CYP1A2, metabolize tri-
cyclics to a lesser extent.4,34,39,40 There is currently no strong 
evidence supporting gene-based dosing recommendations for 
other cytochrome P450 enzymes that metabolize tricyclics.
Potential benefits and risks for the patient
For patients who have existing CYP2D6 and/or CYP2C19 gen-
otyping test results, the potential benefit is identifying those 
patients who are at an elevated risk of experiencing side effects 
or therapeutic failure. For those patients, dose adjustments can 
be made or an alternative agent selected. A limitation inherent 
to most commercially available genotyping tests is that rare or 
de novo variants are not detected. In addition, some alleles are 
not well characterized, resulting in uncertainty when predict-
ing the phenotype for some genetic test results. Genotyping is 
reliable when performed in qualified reference laboratories, but, 
as with any laboratory test, an error can occur. Any errors in 
genotyping or phenotype prediction, along with the presence 
of a rare genomic variant not tested for, could potentially affect 
the patient lifelong.
Caveats: appropriate use and/or potential misuse of 
 genetic tests
The application of genotype-based dosing is most appropriate 
when initiating therapy with a tricyclic. Obtaining a pharma-
cogenetic test after months of drug therapy may be less helpful 
in some instances, given that the drug dose may have already 
been adjusted based on plasma concentrations, response, or side 
effects. Similar to all diagnostic tests, genetic tests are one of 
several pieces of clinical information that should be considered 
before initiating drug therapy.
SUPPLEMENTARY MATERIAL is linked to the online version of the paper at 
http://www.nature.com/cpt
DISCLAIMER
CPIC guidelines reflect expert consensus based on clinical evidence 
and peer-reviewed literature available at the time they are written; they 
are intended only to assist clinicians in decision making and to identify 
questions for further research. New evidence may have emerged since the 
time a guideline was submitted for publication. Guidelines are limited in 
scope and are not applicable to interventions or diseases not specifically 
identified. Guidelines do not account for all individual variations among 
patients and cannot be considered inclusive of all proper methods of care or 
exclusive of other treatments. It remains the responsibility of the health-care 
provider to determine the best course of treatment for a patient. Adherence 
to any guideline is voluntary, with the ultimate determination regarding its 
application to be made solely by the clinician and the patient. CPIC assumes 
no responsibility for any injury to persons or damage to persons or property 
arising out of or related to any use of CPIC’s guidelines, or for any errors or 
omissions.
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